{
    "nct_id": "NCT05060432",
    "official_title": "A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
    "inclusion_criteria": "* Provide a signed written informed consent for the trial\n* Have measurable disease, per RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 or 1.\n* Have adequate organ functions\n* Part 1A/1B/1C/1D/1E/1F: Have histologically or cytologically confirmed advanced or metastatic solid tumor for whom no standard treatment with survival benefit is available\n\nPart 1G (NSCLC):\n\n* Have a histologically confirmed or cytologically confirmed previously untreated stage IV OR stage III not amenable to curative chemoradiotherapy or surgery (AJCC 8th edition) nonsquamous NSCLC OR squamous NSCLC.\n* Are eligible to receive anti-PD(L)1 therapy combined with chemotherapy in first line metastatic setting\n\nPart 2 (H&N cancer)\n\n* Have histologically or cytologically confirmed recurrent advanced or metastatic head and neck squamous cell carcinoma considered incurable by local therapies\n* PD-L1 status positive\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have received any anti-cancer therapy within 4 weeks prior to the first dose\n* Have received a live vaccine within 30 days prior to the first dose\n* Have known primary CNS cancer.\n* Have known CNS metastases unless previously treated and well controlled for at least 1 month\n* Have concomitant second malignancies unless a complete remission was achieved at least 2 years before study entry\n* Have a history of Grade ≥ 2 pneumonitis, active autoimmune disease, or persistent immune-mediated toxicity caused by immune checkpoint inhibitor therapy of Grade ≥ 2\n* Have toxicity (except for alopecia) related to prior anti-cancer therapy and/or surgery unless the toxicity is either resolved, returned to baseline or Grade 1, or deemed irreversible.\n* Have uncontrolled or significant cardiovascular disease\n* Part 1: major surgery within 3 weeks before initiating treatment\n* Part 1: Have received prior radiotherapy within 2 weeks of start of study treatment\n* Part 2 (H&N cancer):\n* Have received prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).\n* Have received prior chemotherapy administered in the recurrent advanced or metastatic setting (except for systemic therapy completed > 6 months prior to screening if given as part of multimodal treatment for locally advanced disease)",
    "miscellaneous_criteria": ""
}